Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Norvasc Patent Term Extension Keeps AmVaz Off The Market Until 2007

Executive Summary

Pfizer's Norvasc (amlodipine besylate) will not face competition from Dr. Reddy's calcium channel blocker AmVaz until 2007 under a federal appeals court ruling

You may also be interested in...



Crestor Patent Battle Could Have Ripple Effect: Is A Salt Equivalent To Base Compound?

Watson filed a 505(b)(2) NDA for a zinc salt of AstraZeneca’s Crestor, which AstraZeneca claims infringes its patent; if Watson prevails more generic manufacturers may pursue this pathway around a patent.

Pfizer, Novartis Learning The VALUE Of Comparative Research

A Novartis-sponsored study comparing Diovan to Pfizer's Norvasc highlights the risk firms take in conducting comparative research

Pfizer, Novartis Learning The VALUE Of Comparative Research

A Novartis-sponsored study comparing Diovan to Pfizer's Norvasc highlights the risk firms take in conducting comparative research

Related Content

UsernamePublicRestriction

Register

PS043503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel